Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
- Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
- Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
- 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.
- Tevogen Bio開始了TVGN 920的臨床前研究，這標誌着其腫瘤治療產品線的啓動。
- Tevogen Bio創建了一個包含HPV基因組中已知蛋白質的數據集，用於識別靶標，從而加快了臨床前過程。
- 每年有550萬名女性感染16/18型HPV；其中每年有20萬名女性被診斷出患有高級別發育不良。
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:MSFT), the world's leading AI company.
新澤西州禾倫，2024年11月5日（環球新聞專線）——Tevogen Bio（「Tevogen」 或 「Tevogen Bio Holdings Inc.」）納斯達克股票代碼：TVGN）是一家臨床階段的特種免疫療法生物技術公司，正在開發用於治療傳染病和癌症的現成的、未經轉基因的T細胞療法。該公司最近宣佈，其人工智能項目 Tevogen.AI 已與全球領先的人工智能公司微軟（納斯達克股票代碼：MSFT）合作。
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.
使用微軟的高級工具套件，Tevogen Bio正在積極研究HPV的潛在治療方法，以創建腫瘤產品組合。該公司已經開發了來自HPV基因組的蛋白質數據集，並正在確定細胞毒性T細胞（CTL）靶標，供其首款腫瘤產品TVGN 920的臨床試驗選擇。通過Tevogen的專有ExactCell技術，對CTL進行培訓，以檢測特定的靶標，然後進行擴展，該公司的目標是爲提供人乳頭瘤病毒特異性CTL治療做好準備。
